CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Open to people ages 18 years and up

• Age greater than or equal to 18 at the time of enrollment
• Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
• Eastern Cooperative Oncology Group performance status 0 or 1
• Adequate hematologic, renal, liver, cardiac and pulmonary organ function

• Prior therapy with an anti-CD19 targeting agent
• Active or chronic graft versus host disease requiring therapy
• Prior allogeneic stem cell transplantation
• Central nervous system (CNS) lymphoma, prior CNS malignancy
• Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
• Primary immunodeficiency
• Current or expected need for systemic corticosteroid therapy
• Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
• Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
• Unwillingness to follow extended safety monitoring